Latest Period
Q2 2026
Security Snapshot
Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO) Institutional Ownership
CUSIP: 019770106
13F Institutional Holders and Ownership History from Q1 2016 to Q2 2026
Institutions Reporting
207
Shares (Excl. Options)
312,661,553
Price
$2.08
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- ALLO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 312,661,553
- Total 13F value
- $651,998,485
- Portfolio coverage rank
- 0%
- Share change
- +128,639,513
- Value change
- +$265,857,728
- Number of holders
- 207
- Shares outstanding
- 347,232,964
- SEC-reported price per share
- $2.10
- Insider filing price
- $2.10
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ALLO - Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 019770106.
- 207 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 208 to 207 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $444,742,204 to $651,998,485.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 207 institutions filings for Q2 2026.
Security key
019770106
Latest holder period
Q2 2026
13F holders
207
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
ALLO full holder history
Allogene Therapeutics, Inc. SEC filings
Allogene Therapeutics, Inc. company facts
Allogene Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 019770106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
ALLO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC | 9% | $30,183,895 | 22,032,040 | Pfizer Inc. | 06 Nov 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 5.6% | +18% | $37,528,939 | +$6,252,698 | 19,445,046 | +20% | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2026 |
| STATE STREET CORP | 5.5% | $36,719,844 | 19,025,826 | STATE STREET CORPORATION | 30 Jun 2026 | |||
| Belldegrun Arie | 3.9% | -30% | $26,268,416 | +$278,296 | 13,610,578 | +1.1% | Arie Belldegrun, M.D. | 30 Jun 2026 |
| Chang David D | 4.9% | -6% | $30,005,544 | +$478,560 | 12,297,354 | +1.6% | David D. Chang, M.D., Ph.D. | 31 Mar 2026 |
| BlackRock, Inc. | 5.3% | $17,633,122 | 11,450,079 | BlackRock, Inc. | 31 Mar 2025 | |||
| FMR LLC | 4.9% | -58% | $15,747,811 | -$20,861,062 | 10,225,851 | -57% | FMR LLC | 28 Feb 2025 |
| CITADEL ADVISORS LLC | 2.8% | -55% | $16,726,493 | -$15,838,116 | 6,855,120 | -49% | Kenneth Griffin | 31 Mar 2026 |
As of 30 Jun 2026, 207 institutional investors reported holding 312,661,553 shares of Allogene Therapeutics, Inc. - Common Stock, $0.001 par value per share (ALLO). This represents 90% of the company’s total 347,232,964 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
72%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.7% | 30,146,963 | +58% | 0% | $62,705,681 |
| Frazier Life Sciences Management, L.P. | 6.5% | 22,446,668 | +491% | 1% | $46,689,069 |
| Pfizer Inc | 6.3% | 22,032,040 | 0% | 28% | $46,928,245 |
| STATE STREET CORP | 5.5% | 19,025,826 | +120% | 0% | $39,573,718 |
| TPG GP A, LLC | 5.4% | 18,716,306 | 0% | 0.78% | $38,929,916 |
| Sio Capital Management, LLC | 3.8% | 13,323,431 | 4.7% | $27,712,736 | |
| PRIMECAP MANAGEMENT CO/CA/ | 3.8% | 13,123,440 | +57% | 0.02% | $27,296,756 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 12,166,636 | +76% | 0% | $25,306,603 |
| FMR LLC | 3.5% | 12,009,043 | +655% | 0% | $24,978,809 |
| CITADEL ADVISORS LLC | 2.9% | 10,087,770 | +48% | 0.01% | $20,982,562 |
| TWO SIGMA INVESTMENTS, LP | 2.2% | 7,784,348 | +45% | 0.01% | $16,191,444 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 7,049,328 | +71% | 0% | $14,666,040 |
| GOLDMAN SACHS GROUP INC | 1.8% | 6,148,959 | +122% | 0% | $12,789,834 |
| GordonMD Global Investments LP | 1.5% | 5,298,000 | +270% | 6.6% | $11,019,840 |
| MARSHALL WACE, LLP | 1.5% | 5,095,408 | +48% | 0.01% | $10,598,449 |
| Patient Square Capital LP | 1.5% | 5,050,000 | +46% | 1.6% | $10,504,000 |
| Aberdeen Group plc | 1.4% | 5,001,752 | +242% | 0.01% | $10,403,644 |
| MILLENNIUM MANAGEMENT LLC | 1.4% | 4,843,889 | +46% | 0.01% | $10,075,289 |
| D. E. Shaw & Co., Inc. | 1.4% | 4,710,735 | +70% | 0.01% | $9,798,329 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.3% | 4,639,283 | -14% | 0% | $9,651,000 |
| MORGAN STANLEY | 1.3% | 4,509,962 | +352% | 0% | $9,380,720 |
| Woodline Partners LP | 1.3% | 4,500,624 | +29% | 0.03% | $9,361,298 |
| Candriam S.C.A. | 1.2% | 4,336,296 | +45% | 0.04% | $9,010,818 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2% | 4,212,078 | +149% | 0% | $8,761,122 |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 3,834,312 | +79% | 0.01% | $7,975,369 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
33
Latest
Q2 2026
Rows shown
1-25 of 33
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 312,661,553 | $651,998,485 | +$265,857,728 | $2.08 | 207 |
| 2026 Q1 | 184,187,050 | $444,742,204 | +$59,358,146 | $2.44 | 208 |
| 2025 Q4 | 162,695,663 | $222,795,319 | +$234,485 | $1.37 | 171 |
| 2025 Q3 | 162,089,712 | $201,004,443 | -$24,367,010 | $1.24 | 167 |
| 2025 Q2 | 183,617,614 | $207,883,293 | -$15,409,926 | $1.13 | 153 |
| 2025 Q1 | 196,986,783 | $288,577,139 | +$11,150,657 | $1.46 | 167 |
| 2024 Q4 | 188,657,885 | $401,850,158 | -$12,907,825 | $2.13 | 170 |
| 2024 Q3 | 164,371,652 | $460,365,265 | -$1,917,859 | $2.80 | 152 |
| 2024 Q2 | 165,184,059 | $384,891,280 | +$75,138,227 | $2.33 | 169 |
| 2024 Q1 | 131,205,694 | $586,006,096 | +$44,997,765 | $4.47 | 158 |
| 2023 Q4 | 122,248,338 | $392,448,357 | -$24,859,731 | $3.21 | 167 |
| 2023 Q3 | 130,384,371 | $413,319,837 | -$17,479,237 | $3.17 | 152 |
| 2023 Q2 | 133,404,417 | $662,853,148 | +$77,627,682 | $4.97 | 168 |
| 2023 Q1 | 117,863,372 | $582,311,658 | +$28,545,426 | $4.94 | 174 |
| 2022 Q4 | 111,615,016 | $701,714,273 | +$16,748,007 | $6.29 | 166 |
| 2022 Q3 | 106,389,695 | $1,148,387,442 | +$56,535,530 | $10.80 | 182 |
| 2022 Q2 | 100,792,050 | $1,148,985,365 | +$110,979,207 | $11.40 | 155 |
| 2022 Q1 | 91,688,120 | $835,872,818 | +$16,130,116 | $9.11 | 173 |
| 2021 Q4 | 85,813,394 | $1,280,601,899 | -$105,097,078 | $14.92 | 168 |
| 2021 Q3 | 86,172,174 | $2,214,699,254 | +$36,168,155 | $25.70 | 165 |
| 2021 Q2 | 86,340,537 | $2,251,293,398 | -$84,504,708 | $26.08 | 175 |
| 2021 Q1 | 86,575,661 | $3,055,834,294 | -$11,800,278 | $35.30 | 167 |
| 2020 Q4 | 87,569,716 | $2,210,441,766 | +$86,472,875 | $25.24 | 160 |
| 2020 Q3 | 83,175,052 | $3,136,521,357 | -$164,131,449 | $37.71 | 158 |
| 2020 Q2 | 86,937,058 | $3,722,235,026 | +$671,195,013 | $42.82 | 170 |